SK chemicals Site Manager- Pouring hot concern, gathering of the most people in history at the
Busan symposium!
- Participating medical experts’ concern focused on the excellent erectile function
of the [ranking 1st in international erectile function index]
- Starting of power hunting through symposiums in major cities such as Seoul,
Daejeon, etc.
SK chemicals(CEO and vice chairman, Chang-Geun Kim) held a symposium regarding Mvix, a new medicine for treating erectile dysfunction, by inviting urologists from Busan/Gyeongnam area through the support from Busan Andrological Society at Busan Lotte Hotel on 17th. This day, the most people gathered in the Busan symposium history, so one could feel hot concern about Mvix.
The first presenter, Nam-Chul Park, professor of urology at Pusan National University Hospital, emphasized with a subject of ‘New PDE5 Inhibitors’, “Mvix not only shows strong effects as much as wining IEF ranking 1st but also shows less revelation rate of side effects compared with existing PDE-5 inhibitors, so the domestic medical sector needs to pay attention to it in safety of medicines as well as erectile function.”
The second presenter, Gwon-Sik Min, professor of urology at Pusan Paik Hospital, expressed the Mvix’s clinical test results, “Mvix obtained 25.7 points(over 26 points for normal erection), the highest points in history, among 30 full points from the IIEF EF(International Index of Erectile Function) measurement, an international index showing the medical effect of erectile dysfunction treating medicines.
Thereafter, professor Min organized the clinical test results, “Compared with existing rival products such as Viagra, etc., Mvix has high selectiveness for PDE-5 so as to show less headache appearing when inhibiting PDE-1 and PDE-6, and reports no color vision trouble so as to be excellent in safety.”
Mvix started to be developed jointly by SK chemicals and IN2GEN, a bio venture, in 1998, successfully finished the pre-clinical test in 2003, the 1st clinical test in 2004(by British Covance), the 2nd clinical test in March 2005 and the 3rd clinical test in March 2006, acquired a license as the 13th new medicine in Korea on July 18, and started to sell by announcing November 1 as the ‘international erection day.’
In-Seok Lee, managing director of marketing in the life science sector of SK chemicals, expressed strong self-confidence about Mvix marketing by saying, “Mvix is the best erectile dysfunction treating medicine furnished with strong erectile function and safety simultaneously so as to be able to lead the erectile dysfunction treating medicine market in 2008.”
SK chemicals is planning to make public Mvix’s strong erectile function and safety through symposiums at major cities across the country such as Seoul, Daejeon, etc. in the new year subsequently this time after Busan/Gyeongnam area.